- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05131399
Contribution of an Off-the-shelf Carbon Ankle Foot Orthosis (AFO) in the Management of Walking Functional Impairment (DEFISTEP)
Single Case Experimental Design (SCED) Comparing an Off-the-shelf Carbon Ankle Foot Orthosis (SPRYSTEP) Versus an off-the Shelf Standard Plastic Ankle Foot Orthosis in the Treatment of Walking Functional Impairment
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Foot drop is a symptom observed in various pathologies including neuro-muscular pathologies of peripheral or central origin. It is a walking disability, causing a deterioration in the patients autonomy and quality of life.
The current medical strategy focuses on various off-the-shelf or custom made devices, depending on the walking functional impairment and the characteristics of foot deformities.
The objective of this study is to assess the superiority in achieving personal goals (set by the patient and the medical team) according to the GAS scale (Goal Attainment Scaling) while wearing the carbon medical device ankle foot orthosis compared to a standard plastic ankle foot orthosis.
Studietyp
Inskrivning (Förväntat)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Philippe THOUMIE, MD PhD
- Telefonnummer: +33 (0)140193534
- E-post: philippe.thoumie@aphp.fr
Studera Kontakt Backup
- Namn: Astrid PICOLET
- Telefonnummer: +33 (0)640392490
- E-post: astrid.picolet@thuasne.fr
Studieorter
-
-
-
Lille, Frankrike
- Har inte rekryterat ännu
- CHU Lille
-
Kontakt:
- Vincent TIFFREAU, MD PhD
- E-post: vincent.tiffreau@chru-lille.fr
-
Nancy, Frankrike
- Har inte rekryterat ännu
- centre Louis PIERQUIN
-
Kontakt:
- Isabelle LOIRET, MD
- E-post: isabelle.loiretpro@gmail.com
-
Paris, Frankrike
- Rekrytering
- Hôpital Rothschild
-
Kontakt:
- Philippe THOUMIE, MD PhD
- Telefonnummer: +33 (0)140193534
- E-post: philippe.thoumie@aphp.fr
-
Strasbourg, Frankrike
- Har inte rekryterat ännu
- CHU Strasbourg
-
Kontakt:
- Amandine HELFER, MD
- E-post: amandine.helfer@ugecam.assurance-maladie.fr
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Patient with a foot levator muscles impairment (single or bilateral drop foot) and / or instability of the back of the foot, associated with a deficit of the triceps
- Patient with inability to stand on tip-toe on one foot
- Patient having signed a free and informed consent
- Patient affiliated or entitled to a social security scheme
Exclusion Criteria:
- Patient with fixed varus-equine foot
- Patient with an unstable skin condition (whether or not treated with additional treatment that may change the footwear)
- Patient with a a foot levator muscles impairment with a deficiency of the quadriceps and hamstrings (knee involvement)
- Patient with uncontrolled spasticity
- Patient for whom foot surgery is planned during the study
- Patient with one of the contraindications to the use of carbon medical device, indicated in the instructions for use
- Patient with one of the contraindications to the use of the standard plastic ankle foot orthosis, indicated in the instructions for use
- Patient with orthopedic comorbidities affecting the musculoskeletal system
- Pregnant woman
- Patient with major cognitive impairment incompatible with participation in a clinical trial
- Patient participating in another clinical investigation conducted to establish the compliance of a MD impacting the evaluation criteria
- Patient who cannot be followed for 12 weeks
- Vulnerable patient according to article L1121-6 of the public health code, persons subject to a measure of judicial protection or unable to consent freely
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Self-comparison
Patients will be fitted with 2 types of ankle foot orthoses, alternately, divided into 4 phases, in the following order: Phase A1: Standard Plastic ankle foot orthosis Phase B1: carbon medical device ankle foot orthosis Phase A2: Standard Plastic ankle foot orthosis Phase B2: carbon medical device ankle foot orthosis Each patient is his own comparator. For all patients, the total duration of the study will be the same, and will correspond to 12 weeks. |
Plastic standard ankle foot orthosis
carbon medical device ankle foot orthosis
Plastic standard ankle foot orthosis
carbon medical device ankle foot orthosis
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Comparison of the ability to achieve personal goals while wearing carbon or standard plastic ankle foot orthosis
Tidsram: 3 times a week during 12 weeks
|
Personal goals achievement is evaluated via the Goal attainment scaling (GAS). Before starting the study, three personal objectives are defined according to patients needs and investigator review. Raw scores ranging from -3 (degradation) to +2 (maximum achievement of the objective) are defined: "-3" corresponding to degradation "-2" corresponding to the initial state "-1" corresponding to a partial objective achievement "0" corresponding to the total objective achievement "+1" corresponding to a better objective achievement "+2" corresponding to the maximum objective achievement. The GAS is filled 3 times a week during 12 weeks. |
3 times a week during 12 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Comparison of patients mobility while wearing carbon or standard plastic ankle foot orthosis
Tidsram: Visits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12).
|
Mobility is evaluated via staircase tests: Time (in minutes) to go up and down 10 steps
|
Visits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12).
|
Comparison of patients walking perimeter while wearing carbon or standard plastic ankle foot orthosis
Tidsram: Visits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)
|
Walking perimeter is evaluated via the Six-minute walk test (6MWT), that measures the distance (in meters) during a 6 minutes walk.
|
Visits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)
|
Comparison of patients fatigue while wearing carbon or standard plastic ankle foot orthosis
Tidsram: Visits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)
|
Patient's fatigue perception is assessed by the patient via the Borg Rating of Perceived Exertion (RPE) scale following mobility and walking perimeter tests The effort rating is based on a scale of 6 to 20 (6, which is "no effort", to 20, which is "maximum effort").
|
Visits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)
|
Comparison of patients stability while wearing carbon or standard plastic ankle foot orthosis
Tidsram: Visits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)
|
Patient's stability is assessed by 2 means:
|
Visits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)
|
Comparison of patients disability evolution according to the investigator while wearing carbon or standard plastic ankle foot orthosis
Tidsram: Visits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)
|
Doctors' opinion on the Patients disability evolution is measured by the Clinical Global Impression - Improvement (CGI-I) questionnaire. The scale has 7 levels of answer from "very strongly improved" which is the better outcome (= 1 point) to "very strongly aggravated" which is the worst outcome (= 7 points) .Intermediate levels are: " Significantly improved "(= 2 points) ; " Slightly improved " (= 3 points) ; " No improvement " (=4 points) ; " Slightly worsen " (=5 points) ; " Seriously worsen" ( = 6 points). The highest score corresponds to the most impairment in quality of life. |
Visits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)
|
Comparison of patients disability evolution according to the patient while wearing carbon or standard plastic ankle foot orthosis
Tidsram: Visits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)
|
Patient's opinion on his disability evolution is measured by the Global Impression of Change (PCI-C). The scale has 7 levels from "no change or condition has got worsed"(worse outcome) to "a great deal better, and a considerable improvement that has made all the difference ( better outcome)". Intermediate levels are: "almost the same, hardly any change at all"; "a little better, but no noticeable change", "somewhat better, but the change has not made any real difference"; "moderately better, and a slight but noticeable change"; "better, and a definite improvement that has made a real and worthwhile difference. |
Visits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)
|
Comparison of pain, gait and balance evolution according to the patient while wearing carbon or standard plastic ankle foot orthosis
Tidsram: Visits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)
|
Pain level is measured by Visual Analogic Scale (VAS) completed by the patient : 0 corresponds to no pain (better outcome) and 10 to maximum pain (worst outcome). Natural gait and confidence in walking are measured by Visual Analogic Scale (VAS) completed by the patient : 0 corresponds to no natural gait or no confidence (worst outcome) and 10 to better natural gait and better confidence (better outcome). Balance is measured by Visual Analogic Scale (VAS) completed by the patient : 0 corresponds to no balance (worst outcome) and 10 to maximum balance (better outcome). |
Visits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)
|
Comparison of tolerance of carbon and standard plastic ankle foot orthosis
Tidsram: Visits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)
|
Tolerance is measured by reported adverse events.
Number and type of serious and non-serious Adverse Device Effects (ADE) are reported.
|
Visits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)
|
Comparison of acceptability and compliance with carbon and standard plastic ankle foot orthosis
Tidsram: Visits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)
|
Cumulative wearing time of the devices under study (indicated by a thermal button inserted into the device) is collected during each phase.
Specific questions on compliance are also asked by the investigator to the patient during the various visits.
|
Visits V0 (Day 0), V1 (between week 2 and 3), V2 (between week 5 and 6), V3 (between week 8 and 9) and V4 (Week 12)
|
Patients satisfaction with carbon and standard plastic ankle foot orthosis
Tidsram: V4 at 12 weeks
|
Patients satisfaction is evaluated at the end of phase B2 regarding the use of the study devices via the "Technology" part of the evaluation towards a technical aid questionnaire (8 questions) and a specific questionnaire.
|
V4 at 12 weeks
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Philippe THOUMIE, MD PhD, Hôpital Rothschild (Paris)
Publikationer och användbara länkar
Allmänna publikationer
- Krasny-Pacini A, Evans J. Single-case experimental designs to assess intervention effectiveness in rehabilitation: A practical guide. Ann Phys Rehabil Med. 2018 May;61(3):164-179. doi: 10.1016/j.rehab.2017.12.002. Epub 2017 Dec 15.
- Barreto LC, Oliveira FS, Nunes PS, de Franca Costa IM, Garcez CA, Goes GM, Neves EL, de Souza Siqueira Quintans J, de Souza Araujo AA. Epidemiologic Study of Charcot-Marie-Tooth Disease: A Systematic Review. Neuroepidemiology. 2016;46(3):157-65. doi: 10.1159/000443706. Epub 2016 Feb 6.
- Gholizadeh H, Abu Osman NA, Eshraghi A, Ali S, Razak NA. Transtibial prosthesis suspension systems: systematic review of literature. Clin Biomech (Bristol, Avon). 2014 Jan;29(1):87-97. doi: 10.1016/j.clinbiomech.2013.10.013. Epub 2013 Oct 29.
- Zucker DR, Ruthazer R, Schmid CH. Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations. J Clin Epidemiol. 2010 Dec;63(12):1312-23. doi: 10.1016/j.jclinepi.2010.04.020. Epub 2010 Sep 22.
- Spieler JF, Amarenco P. [Socio-economic aspects of stroke management]. Rev Neurol (Paris). 2004 Nov;160(11):1023-8. doi: 10.1016/s0035-3787(04)71139-x. French.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- 2021-A02115-36
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Phase A1
-
Institut Pasteur de LilleAvslutad
-
University of ReadingAvslutadMjölkintoleransStorbritannien
-
Ohio State UniversityRekrytering
-
Sheba Medical CenterIndragenFörsämrad balans hos äldreIsrael
-
Tampere UniversityEuropean Union; Academy of Finland; Cancer Society of FinlandAktiv, inte rekryterandeCervikal intraepitelial neoplasi grad 2/3Finland
-
National and Kapodistrian University of AthensAvslutadKirurgisk frisättning av Ai Pulley Trigger Finger
-
University of BarcelonaAvslutad
-
Cairo UniversityOkändLokaliserad sklerodermiEgypten
-
a2 Milk Company Ltd.Avslutad